Adge Pharmaceuticals

ASSET

Asset Summary

A clinical stage orally available small molecule with best-in-class safety
Mechanism of action supports application in diseases with major unmet medical needs
Focus on obesity and metabolic syndrome
Additional rare disease opportunities

NEWS

News

2023

April 30, 2023 16:00 PDT

Adge Pharmaceuticals prepares to evaluate elocalcitol for the treatment of obesity and metabolic syndrome.

Archive >>

Leadership

Kalev Kask PhD

CEO

Dr. Kalev Kask is the founder and Chief Executive Officer of Adge. Before Adge he led the growth of EGeen International into a global clinical research organization as its founding Chief Executive Officer. He is an accomplished dealmaker with an extensive scientific command and commercial acumen. Dr. Kask completed his postgraduate training at Stockholm University, Stanford University and Max-Planck Institute for Medical Research in Heidelberg. Dr. Kask is an inventor on multiple patents and has authored numerous scientific publications.

Adge has assembled an experienced team of drug development experts to take elocalcitol through clinical trials in obesity and related indications.

METABOLIC

Metabolic Syndrome

Presence of at least any three of the following:

Visceral fat reflected in disproportionate fat tissue in and around the abdomen
Insulin resistance
Glucose intolerance
Atherogenic dyslipidemia (high triglycerides (≥150 mg/dL)
High LDL cholesterol and low HDL cholesterol (≤50 mg/dL)
High blood pressure (≥130/85 mmHg)

OSTEOGENESIS

Osteogenesis Imperfecta

Genetic disorder of bone formation characterized by bone fragility and low bone mass
Mutations in type I collagen, collagen-associated proteins and other genes regulating osteoblast activity and signaling
US prevalence of 20,000 to 50,000
No treatment available
New bone formation is required for success in osteogenesis imperfecta